Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.63 |
| ▸ | APP | P05067 | 1/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.60 |
| ▸ | PRKACA | P17612 | 2/20 | 0.60 |
| ▸ | RORC | P51449 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420248 | 0.91 | KMT2A (0.70) | HDAC8KMT2AMEN1LMNATP53 | |
| SCHEMBL4424077 | 0.87 | HDAC8 (0.76) | HDAC8KMT2AMEN1LMNATP53 | |
| SCHEMBL14448969 | 0.85 | MAPT (0.68) | HDAC8KMT2AMEN1LMNATP53 | |
| SCHEMBL4425057 | 0.83 | HDAC8 (0.77) | HDAC8KMT2AMEN1LMNATP53 | |
| SCHEMBL8288761 | 0.83 | MAPT (0.67) | KMT2AMEN1LMNAMAPTALDH1A1 | |
| SCHEMBL14468636 | 0.83 | HDAC8 (0.62) | HDAC8KMT2AMEN1LMNATP53 | |
| SCHEMBL4424123 | 0.81 | PLAU (0.54) | HDAC8KMT2AMEN1LMNAMAPT | |
| SCHEMBL4430271 | 0.79 | HDAC8 (1.00) | HDAC8KMT2AMEN1LMNATP53 | |
| SCHEMBL19380614 | 0.78 | ELOVL1 (1.00) | KMT2AMEN1LMNATP53ELOVL1 | |
| SCHEMBL5903726 | 0.78 | MEN1 (0.59) | HDAC8KMT2AMEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167499-A1 | Biaryl linked hydroxamates: preparation and pharmaceutical applications | A*BIO PTE LTD. (SG) | 2007-07-19 | — | — | US | disclosed |
| US-20070167499-A1 | Biaryl linked hydroxamates: preparation and pharmaceutical applications | A*BIO PTE LTD. (SG) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167499-A1 | Biaryl linked hydroxamates: preparation and pharmaceutical applications | HDAC1, HDAC11, HDAC2 | HDAC8 9/4885KMT2A 80/4885MEN1 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.